May 8, 2018 / 11:40 AM / 14 days ago

BRIEF-Nabriva Therapeutics Reports Q1 Loss Per Share $0.36

May 8 (Reuters) - Nabriva Therapeutics PLC:

* NABRIVA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

* Q1 LOSS PER SHARE $0.36

* Q1 EARNINGS PER SHARE VIEW $-0.59 — THOMSON REUTERS I/B/E/S

* NABRIVA THERAPEUTICS - TOPLINE DATA FROM SECOND PIVOTAL PHASE 3 TRIAL OF LEFAMULIN FOR CABP (LEAP 2) EXPECTED IN SPRING 2018

* AS OF MARCH 31, 2018, NABRIVA THERAPEUTICS HAD $89.6 MILLION IN CASH, CASH EQUIVALENTS AND SHORT-TERM INVESTMENTS

* CASH BALANCE AS OF MARCH 31 IS EXPECTED TO FUND OPERATIONS INTO Q1 OF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below